OCT 29, 2014 7:30 AM PDT

Antibody-based Proteomics: Fast-Tracking Molecular Diagnostics and Target Discovery in Oncology

Speaker
  • Senior Lecturer, School of Biomolecular & Biomedical Science, Co-Director, Cancer Biology & Therapeutics Laboratory, University of Dublin
    Biography
      I obtained my PhD from Trinity College Dublin in 2000. Subsequently, I conducted my postdoctoral training in cancer biology at Columbia University, New York and at the University of Glasgow under the supervision of Prof Nick La Thangue, FRSE. Afterwards, I returned to Ireland as a HRB Career Development Fellow and, in 2009, was employed in a permanent capacity as a Research Fellow in Cancer Biology at UCD within the School of Biomolecular and Biomedical Science and appointed as Senior Lecturer in Cancer Biology within SBBS in 2013. At present, I lead a team of 3 postdoctoral fellows and 3 PhD students (with 4 previous PhD students graduated) funded by the European Commission, Science Foundation Ireland, The Irish Cancer Society and the Irish Research Council for Science, Engineering and Technology. My group has extensive experience in the discovery of molecular determinants of cancer progression (via transcriptomic/proteomic profiling and functional genomic screening) and their clinical translation through the development and automated analysis of tissue microarrays, in addition to their functional analysis using in vitro models and xenograft studies in nude mice. As such, we have established an integrated workflow for the molecular and clinical analysis of central tumourigenic processes that we are currently applying to a number of different tumour types. Based on this work I was elected to the council of the Irish Association for Cancer Research in 2011 and was awarded the 9th St Luke's Young Investigator award in 2012 and an EACR Young Scientist Award in 2009. Additionally, I have been awarded a number of prestigious fellowships, notably from the Health Research Board, the European Molecular Biology Organisation and the Human Frontiers Science Programme and have spent additional time as a Visiting Fellow at the Dana-Farber Cancer Institute/Harvard Medical School and the Netherlands Cancer Institute where I joined the group of Prof Rene Bernards. I have published 33 articles to date in Nature Cell Biology, Nature Reviews Cancer, Oncogene, EMBO Reports, Cancer Research and Clinical Cancer Research among others.

    Abstract

    The effective implementation of personalised cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision-making. Antibody-based proteomics occupies a pivotal space in the cancer biomarker discovery and validation pipeline, facilitating the high-throughput evaluation of candidate markers. Although the clinical utility of these emerging technologies remains to be established, the traditional use of antibodies as affinity reagents in clinical diagnostic and predictive assays suggests that the rapid translation of such approaches is an achievable goal. Furthermore, in combination with, or as alternatives to, genomic and transcriptomic methods for patient stratification, antibody-based proteomics approaches offer the promise of additional insight into cancer disease states. Here, the current status of antibody-based proteomics will be covered, as will its contribution to the development of new assays that are crucial for the realisation of individualised cancer therapy. Moreover, the utility of the digital pathology, particularly pertaining to automated assessment of tissue-derived biomarker expression, will also be described.


    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    AUG 27, 2020 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    AUG 27, 2020 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: August 27, 2020 TIME: 7:00am PT Novel anti-viral medications, including biologics and small molecule inhibitors, as well as serologic diagnostic tool sets are in urgent demand to fight...
    JUN 09, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 09, 2020 10:00 AM PDT
    DATE: June 9, 2020 TIME: 10:00am PT, 1:00pm ET The presentation will first discuss sepsis as a disease and then explain the importance of performing diagnostic tests in the clinical labora...
    Loading Comments...
    Show Resources